Amgen's First Quarter 2013 Revenues Increased 5 Percent to $4.2 Billion and Adjusted Earnings Per Share (EPS) Increased 22 Percent to $1.96
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
THOUSAND OAKS, Calif., April 23, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2013. Key results for the quarter include:
-- Total revenues increased 5 percent to $4,238 million, with 6 percent product sales growth driven by Enbrel(R) (etanercept), XGEVA(R) (denosumab) and Prolia(R) (denosumab).
Help employers find you! Check out all the jobs and post your resume.
THOUSAND OAKS, Calif., April 23, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2013. Key results for the quarter include:
-- Total revenues increased 5 percent to $4,238 million, with 6 percent product sales growth driven by Enbrel(R) (etanercept), XGEVA(R) (denosumab) and Prolia(R) (denosumab).
Help employers find you! Check out all the jobs and post your resume.